# NewAmsterdam Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/newamsterdam-pharma-b-v

- Industry: Biotechnology
- Headquarters: Naarden, Netherlands
- Website: www.newamsterdampharma.com
- Total disclosed funding: $186M
- Latest round: Series A (Nov 1, 2020)
- Investors on record: 12

## About

Based in the Netherlands, NewAmsterdam Pharma specializes in developing innovative treatments for cardiovascular disease and lipid disorders, focusing on unmet patient needs through advanced therapies.NewAmsterdam Pharma B.V. is dedicated to the development of innovative solutions for cardiovascular diseases. Founded in 2019 in Naarden, Netherlands, the company has undergone a strategic shift culminating in a MERGER that raised USD 235.00 mn, leading to total funds raised of USD 160.00 mn. The company’s CEO is Michael Davidson, who brings substantial experience in the pharmaceutical sector. NewAmsterdam Pharma has completed 4 deals to date, indicating a proactive approach to its business strategy.NewAmsterdam Pharma focuses on developing treatments for cardiovascular disease (CVD) and lipid disorders, specifically targeting the unmet needs of patients. The company’s flagship product, obicetrapib, is designed to inhibit cholesteryl ester transfer protein (CETP) to lower low-density lipoprotein cholesterol (LDL-C) levels, thereby reducing cardiovascular risk. Their products target healthcare providers treating patients with high cholesterol and cardiovascular issues across North America, Europe, and select Asian markets.In the most recent year of 2023, NewAmsterdam Pharma reported revenue of USD 14.09 mn, with an EBITDA of USD -182.92 mn. The company's revenue streams derive from direct sales and partnerships with healthcare institutions and pharmaceutical distributors, centered on agreements that facilitate product distribution. Their pricing strategies for obicetrapib and other products align with market standards for innovative pharmaceuticals.NewAmsterdam Pharma plans to leverage its recent MERGER funding of USD 235.00 mn to enhance its product pipeline, focusing on the potential launch of new treatments targeting cardiovascular conditions within the next two years. The company aims to expand its market presence in North America and Europe, along with strategic entry into emerging markets in Asia by 2025. Additionally, NewAmsterdam Pharma has engaged new investor MaasInvest for further venture funding, supporting these growth initiatives.

## Funding rounds

- Series A, Nov 1, 2020, $186M — EQT Life Sciences, Forbion, Medpace, Inc., Kaiser Foundation Hospitals, Ascendant Capital, BVF Partners, GL Capital Group, Janus Henderson Investors, Morningside, Presight Capital, JVC Investment Partners, Population Health Partners

## Investors

- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- Medpace, Inc. — Series A
- Kaiser Foundation Hospitals — Series A
- Ascendant Capital (https://capitalatlas.ai/funds/ascendant-capital) — Series A
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series A
- GL Capital Group (https://capitalatlas.ai/funds/gl-capital-group) — Series A
- Janus Henderson Investors — Series A
- Morningside (https://capitalatlas.ai/funds/morningside) — Series A
- Presight Capital — Series A
- JVC Investment Partners (https://capitalatlas.ai/funds/jvc-investment-partners) — Series A
- Population Health Partners (https://capitalatlas.ai/funds/population-health-partners) — Series A